|
[1]
|
Shimasaki, N., Jain, A. and Campana, D. (2020) NK Cells for Cancer Immunotherapy. Nature Reviews Drug Discovery, 19, 200-218. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Terme, M., Ullrich, E., Delahaye, N.F., et al. (2008) Natural Killer Cell-Directed Therapies: Moving from Unexpected Results to Successful Strategies. Nature Immunology, 9, 486-494. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Blunt, M.D. and Khakoo, S.I. (2020) Activating Killer Cell Immunoglobulin-Like Receptors: Detection, Function and Therapeutic Use. International Journal of Immunogenetics, 47, 1-12. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Becker-Hapak, M.K., Shrestha, N., McClain, E., Dee, M.J., Chaturvedi, P., Leclerc, G.M., et al. (2021) A Fusion Protein Complex That Combines IL12, IL15, and IL18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy. Cancer Immunology Research, 9, 1071-1087. [Google Scholar] [CrossRef]
|
|
[5]
|
Carlsten, M. and Järås, M. (2019) Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells. Frontiers in Immunology, 10, 2357. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Fujisaki, H., Kakuda, H., Shimasaki, N., et al. (2009) Expansion of Highly Cy-totoxic Human Natural Killer Cells for Cancer Cell Therapy. Cancer Research, 69, 4010-4017. [Google Scholar] [CrossRef]
|
|
[7]
|
Raimondo, S., Corrado, C., Raimondi, L., et al. (2015) Role of Exlracel-lular Vesicles in Hematological Malignancies. BioMed Research International, 2015, Article ID: 821613. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Romee, R., Leong, J.W. and Fehniger, T.A. (2014) Utilizing Cytokines to Func-tion-Enable Human NK Cells for the Immunotherapy of Cancer. Scientifica, 2014, Article ID: 205796. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Hodgins, J.J., Khan, S.T., Park, M.M., et al. (2019) Killers 2.0: NK Cell Therapies at the Forefront of Cancer Control. The Journal of Clinical Investigation, 129, 3499-3510. [Google Scholar] [CrossRef]
|
|
[10]
|
Hideshima, T., Ogiya, D., Liu, J., et al. (2021) Immunomodulatory Drugs Activate NK Cells via Both Zap-70 and Cereblon-Dependent Pathways. Leukemia, 35, 177-188. [Google Scholar] [CrossRef] [PubMed]
|